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 ABSTRACT  
Purpose: To estimate the annual loss of productivity from blindness and moderate/ severe visual 
impairment (MSVI) in a population >50 years of age in European Union (EU).  
Methods: We estimated the cost of lost productivity by using three simple models reported in the 
literature based on (1) minimum wage (MW), (2) gross national income (GNI), and (3) purchasing power 
parity-adjusted gross national product (GDP-PPP) losses. In the first two models, assumptions made 
included; that all individuals worked until 65 years of age, and that half of all visual impairment cases 
in the >50 year age group would be between 50 and 65 years of age. Loss of productivity was estimated 
to be 100% for blind individuals and 30% for those with MSVI. None of these models included direct 
medical costs related to visual impairment.  
Results: The estimated number of blind people in the EU population >50 years of age is ~1.28 million, 
with a further 9.99 million living with MSVI. The cost of blindness estimated is 7.81, 6.29 and 17.29 
billion euros based on the three models. MSVI is estimated to cost 18.02, 24.80 and 39.23 billion euros, 
and the total cost of visual impairment 25.83, 31.09 and 56.52 respectively. The estimates from MW 
and adjusted GDP-PPP were generally comparable, whereas GNI model generated higher estimates, 
probably due to lack of adjustment for unemployment.  
Conclusion:  The cost of blindness and MSVI in EU is substantial. Wider use of available cost-effective 
treatment and prevention strategies may reduce the burden significantly.  
  
Introduction 
Blindness and vision impairment (VI) have a substantial impact on individuals’ quality of life1,2,3 
and are important from a societal and public health point of view4 . The Vision Loss Expert 
Group of the Global Burden of Disease study estimated that 285 million people are visually 
impaired worldwide, with 39 million classified as blind4. The profile of the causes of vision loss 
varies across the world, with age-related macular degeneration as the main cause in high-
income countries, and cataract in middle and low-income countries.  Along with glaucoma and 
diabetic retinopathy, these represent the four main sight impairing eye diseases globally and 
in Europe4.   
In the European Union (EU), considerable variations exist across health care systems, economic 
strength, and cost of care. There are clear differences in the allocation of social care and 
resources to blind people across the EU, leading to significant variations of cost burden 
between different countries.  While some prevalence data of VI and blindness are available in 
literature for most EU countries4, studies dealing with the economic impact of vision loss are 
scarce. Where data exists, this is limited to highlighting VI as a chronic condition that is 
important in the measurement of health disability across populations5 . Up-to-date robust 
knowledge on the overall clinical and cost burden of the blindness and VI is vital for policy 
makers in order to ensure that the most appropriate strategies are implemented. 
Economic consequences of VI may be a result of: (i) direct medical costs due to treatment and 
diagnosis of the current condition, or treatment of potential future health consequences (such 
as increased risk of falls, or accidents); (ii) direct non-medical costs (e.g. home improvements 
or transport); or (iii) indirect costs such as lost productivity due to unemployment of the 
individual with VI or their carers. There is no agreed international standard for measuring the 
cost burden of blindness6. Estimating all relevant costs using a methodology comparable across 
different countries is difficult, especially as major cost items are influenced by clinical practice 
and social support systems of any single country. Estimating direct medical cost is particularly 
difficult as these are calculated from country level data on treatment episodes with the 
accuracy of the data and unit costs varying widely in different EU countries. A recent systematic 
review identified only four papers that reported VI-related costs in Europe7 (1 from the UK, 2 
from France and 1 from Germany) and only the UK analysis reported direct medical costs. 
However, estimating the costs due to productivity losses may be feasible by employing macro-
economic approaches, such as those recently suggested by Eckert8 and Smith9.   
The objective of this paper is to estimate the annual economic loss across the EU due to 
reduced productivity from blindness or medium to severe visual impairment (MSVI) in the 
population above 50 years of age. 
 
Materials and Methods 
Cost of lost productivity for 28 EU countries was estimated by using three simple models 
reported in literature based on: minimum wage (MW), gross national income (GNI), and 
purchasing power parity-adjusted gross domestic product (GDP-PPP) losses. The first two 
models followed the same methodology described by Eckert et al8, whereas the third model 
was a modified version of that reported by Smith et al9. We included only costs related to 
productivity losses, and excluded direct medical or non-medical costs. The attempt was made 
to use the most recent data, rather than indexing all data to a single year. Calculations were 
limited to the >50 years old population, and all cost figures were converted to euros, where 
applicable (Table 1). 
Data sources: 
The prevalence of blindness and VI were obtained from the recently published analysis by the 
Vision Loss Expert Group of the Global Burden of Disease Study10, where blindness was defined 
as presenting visual acuity <3/60 in the better eye, and MSVI as presenting visual acuity <6/18 
but ≥3/60 in the better eye. The GBD analysis was based on a systematic review of 243 studies 
published between 1 January 1980 and 31 January 2012, with the country- and age-specific 
prevalence of blindness and MSVI obtained from the authors of this report. The most recent 
estimates were used, which related to year 2010. The population data came from the 2015 
revision of the world population data of the United Nations. Detailed age and gender specific 
data for each EU country were extracted online for 2015. The number of people with blindness 
and MSVI for each country and the age group was estimated by applying the age and country-
specific prevalence rates to the population data.  
MW data were available for most European countries through 2014 Eurostat statistics. Six EU 
countries (Austria, Cyprus, Italy, Denmark, Finland and Sweden) do not have officially set 
minimum wages. For these countries (except Cyprus), 50% of the country-specific average 
wage (AW) values reported by Organisation for Economic Co-operation and Development 
(OECD) was used.  This was in line with the AW/MW ratios for other countries. OECD data was 
not reported for Cyprus, therefore average wage data from Cypriot State Statistical Service 
were obtained online for the same year.  
Data from the statistical office of the European Union (Eurostat) were used for unemployment 
and labour force participation rates (LFPR). GNI per capita (Atlas method, in current US$) and 
GDP-PPP data for each country were available from the World Bank. These were converted to 
euros, using the average exchange rate of European Central Bank for year 2014 (1$=€0.7527).  
Cost calculations  
We used three simple models to calculate the lost revenues due to lack of or reduced 
employment for those who are blind or have MSVI. In the first two models, it was assumed 
that all individuals worked only until 65 years of age, and then dropped out of employment, 
hence would no longer contribute to productivity losses. It has previously been estimated that 
half of all visual impairment cases in the >50 year age group would be those in the 50-65 years 
age group 11 . Therefore, only half of the VI cases over 50 years of age were included in 
calculations. Loss of productivity was estimated to be 100% for the blind people and 30% for 
those with MSVI8. To calculate the blindness productivity losses, total number of people with 
blindness was multiplied with MW, and GNI per capita. To calculate the MSVI productivity 
losses, all of the people with MSVI were multiplied by 30% of the minimum wage, and GNI per 
capita. For these two models, there were no further adjustments done based on employment 
or the LFPRs.  
The third model used the GDP-PPP method, and was based on that published by Smith et al9. 
The loss of productivity were assumed to be 70% for blind people, and 34.5% for MSVI, of 
which 10% accounted for the lost productivity of their carers. In the published model, Smith et 
al assumed that all individuals over 15 years of age were economically active in their base-case, 
but performed adjustments on the basis of general employment and LFPRs. As our study 
population is above 50 years of age, applying general employment and LFPRs would lead to 
overestimation of the productivity losses, with employment and LFPRs progressively reducing 
by advanced age. Although some age-specific data were reported from Eurostat, these were 
not available for each 5-year age band. Therefore it was necessary to make some assumptions. 
In the Eurostat dataset, age-specific LFPR estimates were available for >65 age band. For those 
who are between 50 and 65 years of age, adult LFPRs were applied. For unemployment, age-
specific rates were available for the >55 year population. For 50-55 year group, again adult 
unemployment rates were applied. The productivity losses were first calculated by multiplying 
the total number of people with VI by the disability weights8 (0.7 for blindness and 0.345 for 
MSVI) and by the GDP-PPP per capita. These estimates were then adjusted by the employment 
and LFPRs (Table 2).  
None of these models included direct medical costs as a consequence of visual impairment. 
 Results 
The number of blind people in EU in population who are >50 years of age is estimated to be 
1.28 million, with a further 9.99 million people living with MSVI (Table 3).  
The MW model estimated the cost of blindness at 7.81 billion euros and the cost of MSVI at 
18.02 billion euros. The total cost of visual impairment amounted to 25.8 billion euros for the 
entire EU. Detailed results per each country are given in Table 4. The highest cost burden was 
in Germany (5.48 billion euros), and the lowest was in Malta (11 million euros). 68% of the total 
burden arises from four countries: France, Italy, Germany and the UK. This is larger than the 
proportion of these four countries’ total populations in the EU (53%) (Figure 1). 
Using the GNI method we estimated the cost to be 17.29 billion euros for blindness, 39.23 
billion euros for MSVI, and 56.52 billion euros in total for the visually impaired population.  The 
GDP-PPP model estimated the unadjusted costs to be 24.67, 94.85 and 119.52 billion euros 
respectively. However, when the adjustment factors based on employment and LFPRs (Table 
2), the total costs were similar to those estimated by the MW method (6.29, 24.80 and 31.09 
billion euros) (Table 4).  
To test the robustness of our findings we estimated the confidence intervals based on the 
prevalence data ranges10. Table 5 and Figure 2 present the above mentioned results with their 
confidence intervals. 
Discussion 
This study estimated the economic losses due to blindness and MSVI in EU based on three 
simple macroeconomic models. These findings generally support that visual impairment 
causes a significant cost burden for EU, despite the relatively low prevalence of blindness and 
MSVI.  
In our analysis, the most conservative estimates were produced by the MW method. The GNI 
method produced higher estimates, around a factor of two when compared with the MW 
method. The estimates from the GDP-PPP model, when adjusted by the employment and 
LFPRs, became very close to those estimated by the MW model. This contrasts with the findings 
of Eckert et al8, who reported that adjusted GDP-PPP figures were consistently similar to those 
estimated by the GNI model, and were much higher than those from MW model. This may be 
due to two reasons. First, we had access to age-specific employment and LFPRs from Eurostat, 
which enabled us to refine our estimates. Eckert et al8 used the LFPRs for the 15-64 age band 
in their GDP-PPP model, which may have overestimated the productivity losses for those over 
65 years of age. For example, in our dataset LFPR was as low as 1.72% (Spain) for the older 
than 65 year age group. Therefore we have effectively applied higher adjustment rates than 
those applied by Eckert et al, which resulted in the GDP-PPP estimates approaching the MW 
model. Secondly, although EU countries differ significantly from each other in terms of 
economic strength and purchase power, they still form a more homogenous set than the 
countries included in Eckert et al paper. Furthermore, wealth in the EU is probably more evenly 
distributed than some of the developing countries, which may make MW a better proxy for 
economic losses in this case.  
This analysis has significant limitations, most of which are inherent to macro-economic analysis 
approaches. In MW and GNI models, we assumed no productivity for blind people, and 70% 
productivity for MSVI, and for GDP-PPP model 30% productivity for blind people and 66.5% for 
MSVI. This followed the assumptions made in published models, in order to render 
comparisons possible8,9. These also included an additional 10% productivity loss in the GDP-
PPP model due to carers’ involvement for blind people (and 5% for those with MSVI), derived 
from a study outside of Europe due to the lack of European literature on the subject of carer 
involvement12.   
We have used the country and age-specific prevalence rates estimated by the Vision Loss 
Expert Group of the Global Burden of Disease Study14. We believe that this meta-analysis of a 
comprehensive database (The Global Vision Database) of all population-based blindness/vision 
impairment prevalence studies performed between 1980 and 2012 represents the most 
accurate data in literature to date for both blindness and MSVI prevalence. Although new 
country-specific prevalence estimates will be available in late 2016, our analysis has used the 
currently available estimates of prevalence for 2010. We considered using 2010 as an index 
year, and matching all cost and economic input with actual 2010 data, or alternatively adjusting 
them to 2010 by using inflation / deflation factors where appropriate. However, considering 
the rapid changes in the economic environment in the EU over the last decade, we felt that the 
2010 economic estimates would already be out of date.  Therefore we have applied these 2010-
derived vision blind/vision impairment prevalence rates to the more recent estimates of 
population and economic data from 2014/15.   It is possible that if a decrease in the prevalence 
of visual impairment and blindness has occurred in the EU after 2010 (as occurred in terms of 
age-standardised prevalence and absolute numbers of individuals affected between 1990 and 
2010 10) from improved treatment strategies, our data could represent an over estimation of 
the economic burden as this could have been expected to proportionally reduce.  
Lastly, we applied the disability weights for blindness and MSVI used by Eckert et al8 to produce 
comparable estimates. We do acknowledge that they differ from the latest Global Burden of 
Disease16 ones published by WHO (GBD 2010). 
With these limitations in mind, we feel that the MW method overall offers a simple way of 
estimating the cost burden for visual impairment due to productivity losses in European 
settings. These findings should be treated as conservative estimates in many ways. For 
example, by assuming no productivity for those who are over 65 years of age in MW and GNI 
models, we effectively limited our analysis to a narrow population band, aged between 50 and 
65. Furthermore, our calculations only considered the productivity costs, but the actual cost 
burden to the health systems will be significantly higher when the direct medical and non-
medical costs are included. A recent systematic review suggested that the medical costs for 
people with visual impairment are almost twice higher than those with no visual impairment, 
and that the annual direct medical costs for blind patients would be PPP US$  
14 882–24 1807. In 2003, Meads & Hyde estimated the direct costs for blind people in the UK 
settings, which ranged between £1375 and £17 100 for the first year, followed by £1325–£16 
800 per year for the consecutive years13.  
Unfortunately, recent similar data in EU health systems are scarce in published literature, and 
there is lack of country-specific databases that report VI related direct health care costs, 
making it very difficult to reliably estimate all relevant costs around VI across EU, hence our 
decision not to include medical costs in our estimates. 
The findings of this study are in line with those of similar studies in Japan, Canada, and the 
United States. All studies show how blindness and visual impairment place a heavy burden on 
individuals and society, however direct comparison of results is difficult because of differing 
methodologies applied. 
Roberts et al17 estimated that in 2007, visual impairment affected more than 1.64 million 
people in Japan. Indirect financial costs, estimated through a prevalence-based costing 
method, were 9.9 billion euros (¥1583.5 billion), including productivity losses, care takers' 
costs, and efficiency losses from welfare payments and taxes. Cruess et al18 estimated that in 
2007 the financial cost of vision loss in Canada was 11.9 billion euros ($15.8 billion) per annum 
(inclusive of direct healthcare costs). The study used a prevalence-based approach, based 
primarily on the costs associated with the 5 major causes of visual impairment.  Rein et al19  
estimated that in 2001 the economic burden of visual disorders in the US to be 14.4 billion 
euros ($19.1 billion) (direct costs excluded). The authors used a mixed set of data sources to 
estimate the direct and indirect costs of visual impairment.  
Furthermore, we estimated how total costs of visual impairment would evolve in the future. 
We simply applied the population projections from the Eurostat database20 to our models, 
assuming all the other parameters constant. The cost projections (Figure 3) until 2050 show 
that simply the demographic evolution of the European population would increase even 
further the economic burden. The estimated costs are going to increase in the future based on 
the MW, GNI and GDP-PPP unadjusted methods. On the contrary, with the GDP-PPP adjusted 
method there should be an initial sharp increase in costs but in the long run they would reduce 
although always higher than the current situation. A possible interpretation is that the 
European population will be ageing hence, less individuals are going to be in a working age and 
productive so with the adjustment for productivity the impact of visual impairment is smaller. 
In conclusion, the MW (most conservative) model estimated the total cost of visual impairment 
in the EU to be 25.8 billion euros and 31.9 billion euros by 2050, not accounting for direct costs 
of medical care.  As a comparison, the cost of diabetes Type II in Europe has been estimated to 
be 29 billion euros15. The findings of this analysis should strongly incentivise policy makers to 
work towards developing and implementing appropriate strategies to help visually impaired 
people to find and keep employment. In addition, providing access to cost-effective healthcare 
technologies that have the potential to reduce blindness and MSVI incidence should be given 
priority. For those diseases that are preventable or treatable, early recognition of the condition 
and timely management will reduce the numbers of visually impaired people, which will then 
reduce the overall burden to health and social systems.   
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